Shandong Provincial Key Laboratory of Oral Tissue Regeneration, School of Stomatology, Shandong University, Jinan, Shandong Province, China.
Department of Oral and Maxillofacial Surgery, School of Stomatology, Shandong University, Jinan, Shandong Province, China.
J Oral Pathol Med. 2019 Mar;48(3):201-205. doi: 10.1111/jop.12807. Epub 2019 Feb 3.
Numerous signal transduction pathways are closely associated with the occurrence, development, and prognosis of ameloblastoma (AM). Mitogen-activated protein kinase (MAPK) is a serine/threonine-specific protein kinase that transduces intracellular signals in critical cellular phenomena. A number of recent analyses have reported that the MAPK signaling pathway contributes significantly to AM. High-throughput DNA sequencing methods, such as next-generation sequencing using Illumina have yielded advancements in studies on MAPK signaling pathways and their association with AM; in particular, BRAF V600E is mediated by the activation of the Ras/Raf/MAPK pathway. This review discusses advancements in studies on MAPK signaling pathways and MAPK-targeted inhibitors or antibodies, along with the merits and demerits of MAPK-targeted therapies, finally followed by a discussion regarding more efficient potential MAPK-targeted therapies to treat AM with few side effects, thereby providing novel insights into targeted therapy for AM.
许多信号转导通路与成釉细胞瘤（AM）的发生、发展和预后密切相关。丝裂原活化蛋白激酶（MAPK）是一种丝氨酸/苏氨酸特异性蛋白激酶，可在关键细胞现象中传递细胞内信号。许多最近的分析报告表明，MAPK 信号通路对 AM 有重要贡献。高通量 DNA 测序方法，如使用 Illumina 的下一代测序，已经在 MAPK 信号通路及其与 AM 的关联研究方面取得了进展；特别是，BRAF V600E 通过 Ras/Raf/MAPK 通路的激活来介导。本综述讨论了 MAPK 信号通路以及 MAPK 靶向抑制剂或抗体的研究进展，以及 MAPK 靶向治疗的优缺点，最后讨论了更有效的潜在 MAPK 靶向治疗方法来治疗 AM，副作用少，从而为 AM 的靶向治疗提供新的见解。
